Trial Profile
A Phase II Study of BAY 43-9006 Prior to and Following Nephrectomy in Patients With Metastatic Renal Cell Carcinoma.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 14 Oct 2013
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary)
- Indications Renal cancer
- Focus Therapeutic Use
- 09 Jun 2009 Planned number of patients changed from 30 to 1 as reported by ClinicalTrials.gov.
- 02 Sep 2005 New trial record.